Evidence map›Paper›PMID 38592489›Full record

ArticleCurrent microbiology2024

Metformin Inhibits Zika Virus Infection in Trophoblast Cell Line.

Manuel Adrían Velazquez-Cervantes, Orestes López-Ortega, Victor Javier Cruz-Holguín, Luis Herrera Moro-Huitron, Arturo Flores-Pliego, Ignacio Lara-Hernandez, Mauricio Comas-García, Oscar Villavicencio-Carrisoza, Addy Cecilia Helguera-Reppeto, Haruki Arévalo-Romero and 2 more

Abstract read
PubMed Publisher
In one paragraph

Article in Current microbiology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
2.7field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 2 countries.

Manuel Adrían Velazquez-Cervantes *Laboratorio de Virología Perinatal y Diseño Molecular de Antigenos y Biomarcadores, Departamento de Inmunobioquimica, Instituto Nacional de Perinatología, 11000, Mexico City, Mexico.
Orestes López-Ortega *Institut National de la Santé et de la Recherche Médicale (INSERM) U1151, Institut Necker Enfants Malades, Université Paris Descartes, Sorbonne Paris Cité, Paris, France.
Victor Javier Cruz-HolguínLaboratorio de Virología Perinatal y Diseño Molecular de Antigenos y Biomarcadores, Departamento de Inmunobioquimica, Instituto Nacional de Perinatología, 11000, Mexico City, Mexico.
Luis Herrera Moro-HuitronLaboratorio de Virología Perinatal y Diseño Molecular de Antigenos y Biomarcadores, Departamento de Inmunobioquimica, Instituto Nacional de Perinatología, 11000, Mexico City, Mexico.
Arturo Flores-PliegoDepartamento de Inmunobioquimica, Instituto Nacional de Perinatología, 11000, Mexico City, Mexico.
Ignacio Lara-HernandezSección de Microscopía de Alta Resolución, Centro de Investigación en Ciencias de la Salud y Biomedicina, Universidad Atunóma de San Luis Potrosí, San Luis Potosí, SLP, Mexico.
Mauricio Comas-GarcíaSección de Microscopía de Alta Resolución, Centro de Investigación en Ciencias de la Salud y Biomedicina, Universidad Atunóma de San Luis Potrosí, San Luis Potosí, SLP, Mexico.
Oscar Villavicencio-CarrisozaDepartamento de Inmunobioquimica, Instituto Nacional de Perinatología, 11000, Mexico City, Mexico.
Addy Cecilia Helguera-ReppetoInstitut National de la Santé et de la Recherche Médicale (INSERM) U1151, Institut Necker Enfants Malades, Université Paris Descartes, Sorbonne Paris Cité, Paris, France.
Haruki Arévalo-RomeroLaboratorio de Inmunología y Microbiología Molecular, División Académica Multidisciplinaria de Jalpa de Méndez, Universidad Juárez Autónoma de Tabasco, Jalpa de Méndez, Mexico.
Edgar Ricardo Vázquez-MartínezUnidad de Investigación en Reproducción Humana, Instituto Nacional de Perinatología-Universidad Nacional Autónoma de México, 11000, Mexico City, Mexico.
Moises León-Juárez *Laboratorio de Virología Perinatal y Diseño Molecular de Antigenos y Biomarcadores, Departamento de Inmunobioquimica, Instituto Nacional de Perinatología, 11000, Mexico City, Mexico. moisesleoninper@gmail.com.
Instituto Nacional de Perinatología · MXAutonomous University of San Luis Potosí · MXInserm · FRInstitut Necker Enfants Malades · FRUniversidad Juárez Autónoma de Tabasco · MX

Funding

Instituto Nacional de Perinatologia 212250-3210-21007-03-16
6 · The paper itself

Abstract

Zika virus (ZIKV) infections have been associated with severe clinical outcomes, which may include neurological manifestations, especially in newborns with intrauterine infection. However, licensed vaccines and specific antiviral agents are not yet available. Therefore, a safe and low-cost therapy is required, especially for pregnant women. In this regard, metformin, an FDA-approved drug used to treat gestational diabetes, has previously exhibited an anti-ZIKA effect in vitro in HUVEC cells by activating AMPK. In this study, we evaluated metformin treatment during ZIKV infection in vitro in a JEG3-permissive trophoblast cell line. Our results demonstrate that metformin affects viral replication and protein synthesis and reverses cytoskeletal changes promoted by ZIKV infection. In addition, it reduces lipid droplet formation, which is associated with lipogenic activation of infection. Taken together, our results indicate that metformin has potential as an antiviral agent against ZIKV infection in vitro in trophoblast cells.

Indexed as

MetforminZika VirusZika Virus InfectionAntiviral AgentsCell Line, TumorFemaleHumansInfant, NewbornPregnancyTrophoblastsAntiviral AgentsMetformin

Identifiers

PMID38592489
OpenAlexW4394607849

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.